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ell survival depends on proper propagation of pro-
tective signals through intracellular signaling inter-
mediates. We report here that calponin homology
domain–containing integrin-linked kinase (ILK)–binding
protein (CH-ILKBP), a widely expressed adaptor protein
localized at plasma membrane-actin junctions, is essential
for transmission of survival signals. Cells that are depleted
 
of CH-ILKBP undergo extensive apoptosis despite the presence
of cell–extracellular matrix contacts and soluble growth
factors. The activating phosphorylation of protein kinase B
(PKB/Akt), a key regulator of apoptosis, is impaired in the
absence of CH-ILKBP. Importantly, loss of CH-ILKBP prevents
the membrane translocation of PKB/Akt. Furthermore, forced
membrane targeting of PKB/Akt bypasses the requirement
C
 
of CH-ILKBP for the activating phosphorylation of PKB/Akt,
suggesting that CH-ILKBP is required for the membrane
translocation but not the subsequent phosphorylation of
PKB/Akt. Finally, we show that loss of CH-ILKBP is also
required for the full activation of extracellular signal–regulated
kinase (ERK)1/2. However, restoration of the PKB/Akt acti-
vation is sufﬁcient for protection of cells from apoptosis
induced by the depletion of CH-ILKBP despite the persistent
suppression of the ERK1/2 activation. Thus, CH-ILKBP is an
important component of the prosurvival signaling pathway
functioning primarily by facilitating the membrane trans-
location of PKB/Akt and consequently the activation of
PKB/Akt in response to extracellular survival signals.
 
Introduction
 
Cell survival is a fundamental process that requires cellular
interactions with appropriate extracellular survival factors
(e.g., growth factors and extracellular matrix) and proper
propagation of the survival signals through intracellular
signaling pathway. Recent studies have established protein
kinase B (PKB)*/Akt as a key signaling intermediate in the
survival pathway (for reviews see Downward, 1998; Brazil
and Hemmings, 2001; Lawlor and Alessi, 2001; Cantley,
2002). PKB/Akt activation is a multistep process involving
coordinated actions of several catalytic and noncatalytic
molecules. An early and obligatory step in the activation of
PKB/Akt is its translocation from cytosol to the plasma
membrane, often near or at cell–cell or cell–matrix contacts
(Watton and Downward, 1999). The membrane-bound
PKB/Akt is then phosphorylated at Ser473 near the COOH
terminus and Thr308 in the activation loop by upstream
protein kinases (Alessi et al., 1996), which leads to full acti-
vation of PKB/Akt. Activated PKB/Akt, in turn, phosphory-
lates several key apoptosis mediators, resulting in protection
of cells from apoptosis. Therefore, identification of factors
that participate in the cellular control of PKB/Akt activation
is essential for understanding the mechanism by which cells
control apoptosis.
Recent development of specific and efficient gene silencing
in mammalian cells by RNA interference (RNAi) has allowed
us to critically evaluate the role of proteins in cell survival
and the mechanism whereby they function. Calponin homol-
ogy domain–containing integrin-linked kinase (ILK)–binding
protein (CH-ILKBP; Tu et al., 2001) (also known as actopaxin
[Nikolopoulos and Turner, 2000] or 
 
 
 
-parvin [Olski et al.,
2001]) is a member of the CH-ILKBP/actopaxin/affixin/
parvin protein family (Wu and Dedhar, 2001) that interacts
with ILK, paxillin, and actin and clusters at the plasma
membrane-actin junctions. In this study, we show that CH-
ILKBP is an important antiapoptotic protein. Furthermore,
we provide evidence showing that CH-ILKBP functions in
cell survival by facilitating the membrane translocation of
PKB/Akt and consequently the activation of PKB/Akt in
response to extracellular survival signals.
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*Abbreviations used in this paper: CH-ILKBP, calponin homology domain–
 
containing ILK-binding protein; ERK, extracellular signal–regulated
kinase; IGF, insulin-like growth factor; ILK, integrin-linked kinase;
PKB, protein kinase B; RNAi, RNA interference; siRNA, small interfer-
ing RNA.
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Results and discussion
 
CH-ILKBP is crucial for cell survival
 
We employed RNAi to deplete CH-ILKBP in human cells.
Transfection of HeLa cells with a CH-ILKBP small interfer-
ing RNA (siRNA) (Fig. 1 A, lane 1) but not an irrelevant
control RNA (Fig. 1 A, lane 2) resulted in a near total loss of
CH-ILKBP. Probing the same samples with an antiactin an-
tibody showed that the level of actin was not altered (Fig. 1
B). Thus, the CH-ILKBP siRNA effectively suppresses the
expression of CH-ILKBP without globally altering protein
expression. CH-ILKBP forms a ternary complex with ILK
and PINCH-1 in cells (Tu et al., 2001). Consistent with
this, depletion of CH-ILKBP modestly reduced the levels of
ILK (Fig. 1 C) and PINCH-1 (Fig. 1 D). The suppression
of CH-ILKBP expression in the CH-ILKBP siRNA trans-
fectants (Fig. 1 E) but not the control siRNA transfectants
(Fig. 1 F) was confirmed by immunofluorescent staining.
Staining of the cells with an antibody to paxillin (a marker
of focal adhesions) showed that focal adhesions were formed
in the CH-ILKBP–deficient cells (Fig. 1 G) and the control
cells (Fig. 1 H). Moreover, staining of the cells with an anti-
ILK antibody showed that a substantial amount of ILK (or
proteins that share a common epitope with ILK) was clus-
tered at focal adhesions (Fig. 1 I) despite the suppression of
CH-ILKBP expression. To further analyze this, we trans-
fected HeLa cells expressing GFP-ILK or GFP–PINCH-1
with CH-ILKBP siRNA and the control RNA, respectively.
GFP-ILK (Fig. 1 L) and GFP–PINCH-1 (Fig. 1 N) local-
ized to cell–matrix adhesions in both the CH-ILKBP siRNA
transfectants (Fig. 1, K and M) and the control transfectants
(unpublished data). Although depletion of CH-ILKBP pre-
vented neither the formation of cell–matrix adhesions nor
the localization of ILK and PINCH-1 to the adhesion sites,
it induced a dramatic increase of apoptosis as revealed by the
appearance of a large percentage of TUNEL-positive cells
(Fig. 2, A and B). Analyses of the activity of caspase-3, a key
mediator of apoptosis, showed that its activity was markedly
increased in the absence of CH-ILKBP (Fig. 2 C). These re-
sults suggest that (a) CH-ILKBP is essential for cell survival
albeit it is not absolutely required for the formation of cell–
matrix adhesions and (b) CH-ILKBP acts in the cell survival
pathway upstream of caspase-3.
 
CH-ILKBP regulates PKB/Akt phosphorylation
 
To gain insight into the mechanism by which CH-ILKBP
functions in cell survival, we analyzed the effect of loss of
Figure 1. RNAi suppression of CH-ILKBP expression. (A–D) HeLa cells (lane 3), 
CH-ILKBP siRNA (lane 1), or the control RNA (lane 2) transfectants were analyzed by 
Western blotting with anti–CH-ILKBP mAb 3B5 (A, 10  g proteins/lane), polyclonal 
antiactin antibody (B, 1  g proteins/lane), anti-ILK mAb 65.1 (C, 10  g proteins/lane), 
and polyclonal anti–PINCH-1 antibody (D, 10  g proteins/lane). As we showed 
previously (Li et al., 1999), an additional protein band with an apparent molecular 
mass of  85 kD, which likely represents a protein that shares an epitope with ILK, 
was also detected by the anti-ILK mAb (C). (E–J) The CH-ILKBP siRNA (E, G, and I) 
and the control siRNA (F, H, and J) transfectants were stained with mAbs recognizing 
CH-ILKBP (E and F), paxillin (G and H), and ILK (I and J), respectively. Bar, 25  m. 
(K–N) HeLa cells expressing GFP-ILK or GFP–PINCH-1 were transfected with CH-ILKBP 
siRNA and stained with anti–CH-ILKBP mAb 3B5 and a Rhodamine red
TM–conjugated 
anti–mouse IgG antibody. Cells were observed under a fluorescence microscope with 
rhodamine (K and M) and GFP (L and N) filters. Bar, 15  m.T
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CH-ILKBP on the activating phosphorylation of PKB/Akt,
a key membrane-proximal survival signaling intermediate
that is activated in response to growth factors and cell–
matrix adhesion. Stimulation of HeLa cells with serum (Fig.
3 A, lane 6) or insulin-like growth factor (IGF)-1 (Fig. 3 B,
lane 6) induced phosphorylation of PKB/Akt at both Ser473
and Thr308. However, the activating phosphorylation of
PKB/Akt was impaired in the CH-ILKBP–deficient cells
(Fig. 3, A and B, lane 4 compared with 6) but not the con-
trol cells (Fig. 3, A and B, lane 5 compared with 6). In paral-
lel experiments, a similar amount of PKB/Akt protein was
detected in the CH-ILKBP–deficient cells and the control
cells (Fig. 3, A and B, lanes 1–6). Loss of CH-ILKBP did
not alter the protein level or phosphorylation of phospho-
inositide-dependent protein kinase 1 (PDK1) (Fig. 3, A and
B), an upstream Ser/Thr kinase responsible for the Thr308
phosphorylation of membrane-bound PKB/Akt. Collec-
tively, these results suggest that CH-ILKBP is critically in-
volved in the cellular phosphorylation of PKB/Akt without
altering the protein level or phosphorylation of PDK1.
PKB/Akt can be activated not only by soluble survival
factors but also by integrin-mediated cell–matrix adhesion
(Khwaja et al., 1997; King et al., 1997; Gu et al., 2002). To
test whether CH-ILKBP is required for cell adhesion-induced
activating phosphorylation of PKB/Akt, we placed the CH-
Figure 2. CH-ILKBP is crucial for cell survival. (A) HeLa cells, the 
control transfectants, and the CH-ILKBP siRNA transfectants were 
fixed and then incubated in the TUNEL reaction mixture, washed, 
and stained with DAPI. Apoptotic (TUNEL-positive) cells were de-
tected by fluorescence microscopy. (B) The percentages of TUNEL-
positive cells were calculated by counting at least 800 cells from 
five randomly selected fields. Data represent means   SD. (C) The 
activities of caspase-3 in HeLa cells and the control and CH-ILKBP 
siRNA transfectants were quantified. Data represent means   SD 
from two independent experiments.
Figure 3. CH-ILKBP regulates PKB/Akt phosphorylation. (A and B) 
The CH-ILKBP siRNA transfectants (lanes 1 and 4), the control RNA 
transfectants (lanes 2 and 5), and the parental HeLa cells (lanes 3 
and 6) were serum starved (lanes 1–3) and stimulated with 10% FCS 
(A, lanes 4–6) or 2 ng/ml IGF-1 (B, lanes 4–6) for 10 min. The cell 
lysates (10  g/lane) were analyzed by Western blotting with antibodies 
recognizing Akt, phospho-Akt(Ser473), phospho-Akt(Thr308), 
phosphor-PDK1(Ser241), and PDK1, respectively. (C) The CH-ILKBP 
siRNA transfectants (lanes 1 and 2), the control RNA transfectants 
(lanes 3 and 4), and HeLa cells (lanes 5 and 6) were kept in suspension 
for 2 h and then either harvested (lanes 1, 3, and 5) or allowed to 
adhere on laminin-coated plates for 30 min (lanes 2, 4, and 6). The 
cell lysates (15  g/lane) were analyzed by Western blotting with 
antibodies recognizing Akt, phospho-Akt(Ser473), and phospho-
Akt(Thr308), respectively.T
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ILKBP–deficient cells and CH-ILKBP–expressing cells on
laminin. Adhesion of the CH-ILKBP–expressing cells to
laminin induced phosphorylation of PKB/Akt at both
Ser473 and Thr308 (Fig. 3 C, lanes 4 and 6). By marked
contrast, the phosphorylation of PKB/Akt was impaired in
the absence of CH-ILKBP (Fig. 3 C, lane 2). Together,
these results suggest that CH-ILKBP is required for both the
soluble survival factor– and the matrix adhesion–induced
phosphorylation of PKB/Akt.
 
CH-ILKBP functions in the PKB/Akt activation by 
facilitating the membrane translocation of PKB/Akt
 
We next investigated the mechanism by which CH-ILKBP
functions in the activating phosphorylation of PKB/Akt. Be-
cause membrane translocation of PKB/Akt precedes and is es-
sential for the activating phosphorylation of PKB/Akt (And-
jelkovic et al., 1997; Scheid et al., 2002), we tested whether
CH-ILKBP is required for the membrane translocation of
PKB/Akt. Stimulation of HeLa cells or the control cells with
IGF-1 induced translocation of PKB/Akt from cytosol to the
membrane (Fig. 4 A, lanes 4 and 6), where it was phosphory-
lated at Ser473 (Fig. 4 B, lanes 4 and 6) and Thr308 (Fig. 4
C, lanes 4 and 6). By marked contrast, the PKB/Akt mem-
brane translocation (Fig. 4 A, lane 2) and phosphorylation at
Ser473 (Fig. 4 B, lane 2) and Thr308 (Fig. 4 C, lane 2) were
impaired in the absence of CH-ILKBP. Probing the sam-
ples with an anti–CH-ILKBP antibody confirmed that CH-
ILKBP was depleted in the membrane and the cytosol frac-
tions of the CH-ILKBP siRNA transfectants (Fig. 4 D, lanes
1 and 2). Loss of CH-ILKBP did not significantly alter the
amount of PDK1 associated with the membrane (Fig. 4 E,
lanes 1 and 2). These results indicate that CH-ILKBP is re-
quired for the membrane translocation of PKB/Akt but not
the association of PDK1 with the membrane.
We next sought to confirm that CH-ILKBP participates
in the activation of PKB/Akt by facilitating the membrane
translocation of PKB/Akt. We reasoned that if facilitating
the membrane translocation of PKB/Akt is the primary
function of CH-ILKBP in the activation of PKB/Akt, loss of
CH-ILKBP should not impair phosphorylation of mem-
brane-bound PKB/Akt. To test this, we expressed myristoy-
lated PKB/Akt in HeLa cells (Fig. 4 F, lanes 1–4). The
Figure 4. Loss of CH-ILKBP impairs the 
membrane translocation of PKB/Akt. 
(A–E) The CH-ILKBP siRNA-transfectants 
(lanes 1 and 2), the control transfectants 
(lanes 3 and 4), and the parental HeLa 
cells (lanes 5 and 6) were serum starved 
(lanes 1, 3, and 5) or stimulated with 2 
ng/ml IGF-1 for 5 min (lanes 2, 4, and 6). 
Samples from the cytosol (10  g proteins/
lane) and the membrane (corresponding 
to 20  g cytosol proteins/lane) fractions 
were analyzed by Western blotting with 
antibodies recognizing Akt (A), phospho-
Akt(Ser473) (B), phospho-Akt(Thr308) 
(C), CH-ILKBP (D), and PDK1 (E), 
respectively. (F) HeLa cells were trans-
fected with the pUSEamp( )/myr-Akt1 
vector encoding myristoylated PKB/Akt 
(lanes 1–4) or a pUSEamp( ) vector 
lacking Akt sequence as a control (lanes 
5–8). The myristoylated PKB/Akt and the 
control vector transfectants were then 
transfected with the CH-ILKBP siRNA 
(lanes 1, 2, 5, and 6) or the control RNA 
(lanes 3, 4, 7, and 8). The cell lysates 
(10  g/lane) were analyzed by Western 
blotting with antibodies recognizing 
Akt, phospho-Akt(Ser473), phospho-
Akt(Thr308), and CH-ILKBP, respectively.T
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myristoylated PKB/Akt, which is constitutively bound to
the membrane (Andjelkovic et al., 1997), was phosphory-
lated at Ser473 and Thr308 in the absence (Fig. 4 F, lanes 1
and 2) and the presence (Fig. 4 F, lanes 3 and 4) of CH-ILKBP.
In parallel experiments, stimulation with IGF-1 induced phos-
phorylation of wild-type PKB/Akt at Ser473 and Thr308 in
the presence (Fig. 4 F, lane 8) but not the absence (Fig. 4 F,
lane 6) of CH-ILKBP. Thus, although CH-ILKBP is re-
quired for the Ser473 and Thr308 phosphorylation of wild-
type PKB/Akt, it is not required for the Ser473 and Thr308
phosphorylation of the membrane-bound PKB/Akt, con-
firming that CH-ILKBP functions in the cellular activation
of PKB/Akt by facilitating the membrane translocation but
not the phosphorylation reaction of PKB/Akt.
 
PKB/Akt is the primary target of CH-ILKBP 
in cell survival
 
Stimulation of cells with serum induced phosphorylation of
not only PKB/Akt but also ERK1/2 and p38 MAPK (Fig. 5
A, lanes 5 and 6). Loss of CH-ILKBP modestly inhibited se-
rum induced phosphorylation of ERK1/2 (Fig. 5 A, lane 4
compared with 5 and 6) but not that of p38 MAPK (Fig. 5
A, lanes 4–6). A modest inhibitory effect on IGF-1–induced
ERK1/2 phosphorylation has also been observed (Fig. 5 B,
lane 4). To test whether PKB/Akt is the primary target of
CH-ILKBP in cell survival, we analyzed the effect of expres-
sion of the constitutively active PKB/Akt on apoptosis in-
duced by the loss of CH-ILKBP. Expression of myristoy-
lated PKB/Akt, which overrode the inhibition on the
membrane translocation, and consequently the activating
phosphorylation of PKB/Akt induced by the loss of CH-
ILKBP (Fig. 4 F), did not release the modest inhibition of
ERK1/2 phosphorylation (Fig. 5 C, lane 2 compared with
4). However, it did rescue cells from apoptosis induced by
the loss of CH-ILKBP (Fig. 5, D and E). In control experi-
ments, expression of the constitutively active PKB/Akt did
not release the siRNA-mediated suppression of CH-ILKBP
expression (Fig. 5 F). Thus, PKB/Akt, and specifically the
membrane translocation of PKB/Akt, is the primary target
of CH-ILKBP in protection of cells from apoptosis.
Figure 5. PKB/Akt is the primary target 
of CH-ILKBP in cell survival. (A and B) 
CH-ILKBP modulates ERK phosphory-
lation. The CH-ILKBP siRNA transfectants 
(lanes 1 and 4), the control transfectants 
(lanes 2 and 5), and HeLa cells (lanes 3 
and 6) were serum starved (lanes 1–3) 
and then stimulated with 10% FCS (A, 
lanes 4–6) or 2 ng/ml IGF-1 (B, lanes 4–6) 
for 10 min. The cell lysates (10  g/lane) 
were analyzed by Western blotting with 
antibodies recognizing Erk1/2 (p44/42), 
phosphor-Erk1/2(Thr202/Tyr204) (phos-
phor-p44/42), and phosphor-p38 MAPK 
(Thr180/Tyr182), respectively. (C) The 
myristoylated PKB/Akt-expressing cells 
(see Fig. 4 F) were transfected with the 
CH-ILKBP siRNA (lanes 1 and 2) or the 
control RNA (lanes 3 and 4). The cells 
were serum starved (lanes 1 and 3) and 
then stimulated with 2 ng/ml IGF-1 (lanes 
2 and 4) for 10 min. The cell lysates (10 
 g protein/lane) were analyzed by Western 
blotting with antibodies recognizing Erk1/2 
and phosphor-Erk1/2(Thr202/Tyr204), 
respectively. (D–F) Expression of 
membrane-bound PKB/Akt bypasses 
the requirement of CH-ILKBP for cell 
survival. Apoptotic cells were detected 
using TUNEL (D), and the percentages 
of the TUNEL-positive cells (E) were 
calculated as in the legend to Fig. 2. 
Vector, HeLa cells transfected with a 
pUSEamp( ) vector lacking Akt sequence 
and the control RNA; CH-ILKBP( )   
Vector, HeLa cells transfected with a 
pUSEamp( ) vector lacking Akt sequence 
and the CH-ILKBP siRNA; CH-ILKBP( )   
myr-Akt, HeLa cells transfected with
the pUSEamp( )/myr-Akt1 vector 
encoding myristoylated PKB/Akt and 
the CH-ILKBP siRNA. (F) The lysates 
(10  g/lane) from the transfectants were 
analyzed by Western blotting with anti–
CH-ILKBP mAb 3B5.T
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The results presented above have established CH-ILKBP
as an important antiapoptotic protein, since depletion of
CH-ILKBP results in a dramatic increase of apoptosis. In
addition, they shed light on the mechanism by which CH-
ILKBP functions in protection of cells from apoptosis. CH-
ILKBP is clearly required for the activating phosphorylation
of PKB/Akt in response to extracellular survival factors. Al-
though CH-ILKBP is also involved in the modulation of
phosphorylation of Erk1/2, which likely plays a role in the
regulation of other cellular processes such as proliferation or
differentiation, the primary function of CH-ILKBP in the
survival pathway is to regulate the activation of PKB/Akt,
since expression of constitutively active PKB/Akt is suffi-
cient for protection of cells from apoptosis induced by the
loss of CH-ILKBP despite the persistent suppression of the
ERK1/2 phosphorylation.
How does CH-ILKBP regulate the activation of PKB/
Akt? PKB/Akt activation is a complex process involving at
least two major steps, namely the membrane translocation
and the subsequent phosphorylation of PKB/Akt at Ser473
and Thr308. Therefore, the activation of PKB/Akt could be
regulated at either the membrane translocation or the phos-
phorylation steps. Our findings that (a) loss of CH-ILKBP
impairs the membrane translocation of PKB/Akt and (b)
forced targeting of PKB/Akt to the membrane restores its
phosphorylation at both Ser473 and Thr308 suggest that
CH-ILKBP is required for the membrane translocation but
not the subsequent phosphorylation reaction of PKB/Akt.
Cell matrix adhesion is crucial for cell survival (Meredith
et al., 1993; Frisch and Screaton, 2001; Lee and Juliano,
2002; Miranti and Brugge, 2002). Watton and Downward
(1999) have shown that during PKB/Akt activation, PKB/
Akt is translocated to sites near or at cell matrix or cell–cell
contacts. The finding that CH-ILKBP is required for the
membrane translocation of PKB/Akt raises an interesting
possibility that the close vicinity of cell matrix contacts and
the PKB/Akt membrane translocation sites may reflect a
need for a local event involving certain cell matrix adhesion
components (e.g., CH-ILKBP) during the membrane trans-
location process. It is interesting to note that although hu-
man CH-ILKBP (Tu et al., 2001) and affixin (Yamaji et al.,
2001) are encoded by two different genes, they share signifi-
cant sequence similarity, particularly in the CH2 domains
that mediate the ILK binding. Overexpression of the ILK-
binding CH2 fragments of CH-ILKBP/actopaxin or affixin
in mammalian cells altered the dynamics of cell shape
change but did not block the eventual establishment of cell
matrix adhesions (Nikolopoulos and Turner, 2000; Tu et
al., 2001; Yamaji et al., 2001), possibly due to the presence
of other linkages between extracellular matrix and the actin
cytoskeleton. In this study, we have found that cell matrix
adhesion structures were formed in the absence of CH-
ILKBP (Fig. 1). Thus, the impairment of PKB/Akt mem-
brane translocation induced by the depletion of CH-ILKBP
is not caused by a lack of cell matrix contacts but instead by
a compositional change of the cell matrix contacts.
Because ILK is involved in the activation of PKB/Akt
(Delcommenne et al., 1998; Lynch et al., 1999), a simple
mechanism would be that loss of CH-ILKBP impairs the
proper localization of ILK and thereby inhibits the activa-
 
tion of PKB/Akt. Indeed, mutations within the COOH-ter-
minal domain of ILK that disrupt the binding of the CH2
domains of CH-ILKBP/actopaxin abolish the localization of
ILK to cell matrix adhesions (Nikolopoulos and Turner,
2002; Zhang et al., 2002). However, depletion of CH-
ILKBP does not appear to prevent the localization of ILK to
cell matrix adhesions, suggesting that other proteins bind-
ing to the same ILK site (e.g., other members of the CH-
ILKBP/actopaxin/affixin/parvin family) could play a similar
role supporting the localization of ILK to the adhesion sites.
Although there likely exist multiple ILK-binding proteins
that can support the localization of ILK to the adhesion
sites, CH-ILKBP is indispensable for the PKB/Akt mem-
brane translocation and cell survival. Thus, although our
data do not necessarily rule out a role of CH-ILKBP in ILK
localization, they do not support a model in which CH-ILKBP
functions in the PKB/Akt activation by merely facilitating
the localization of ILK to cell matrix adhesion sites.
The mechanism by which ILK functions in the activa-
tion of PKB/Akt is complex and is an area under intensive
research. Overexpression of ILK, but not that of an ILK
point mutant (GH31R) in which Glu359 in the COOH-
terminal domain was substituted with Lys, enhanced the
Ser473 phosphorylation of PKB/Akt (Delcommenne et al.,
1998). In addition, Delcommenne et al. (1998) have
found that ILK can phosphorylate PKB/Akt at Ser473 in
vitro and therefore proposed that ILK regulates PKB/Akt
activation by direct phosphorylation of Ser473. Lynch et
al. (1999) have confirmed that overexpression of ILK pro-
motes the Ser473 phosphorylation of PKB/Akt, but they
proposed that ILK regulates the Ser473 phosphorylation of
PKB/Akt by an indirect mechanism, since ILK mutants
bearing mutations at sites that are predicted to be essential
for kinase activity were also able to promote the Ser473
phosphorylation. The finding that ILK possesses protein
kinase activity has been confirmed by several reports,
and the promotion of the PKB/Akt activation by ILK has
been repeatedly observed (for review see Wu and Dedhar,
2001). However, biochemical purification and character-
ization of the Ser473 kinase suggest that the Ser473 kinase
is distinct from ILK (Hill et al., 2002). The findings pre-
sented in this paper raise an interesting possibility, which is
not necessarily mutually exclusive with the model involv-
ing ILK kinase activity, that ILK and CH-ILKBP work in
concert in facilitating the membrane translocation and
consequently the activation of PKB/Akt. This possibility is
supported by recent findings that the dominant-negative
ILK GH31R mutant is incapable of binding to CH-ILKBP
(Nikolopoulos and Turner, 2002). In further supporting
of this, we have found that overexpression of an ILK-bind-
ing CH-ILKBP COOH-terminal fragment inhibited the
activation of PKB/Akt (unpublished data). Clearly, future
studies are required to further test this possibility.
Apoptosis is a fundamental process that is tightly regu-
lated in organogenesis and in cell and tissue homeostasis.
Dysregulation of apoptosis is a major cause of human dis-
eases such as cancers. Therefore, the work presented in this
report not only provides new information on the regulation
of PKB/Akt membrane translocation and apoptosis but also
suggest that CH-ILKBP, given its crucial role in the cellularT
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activation of PKB/Akt, could serve as a useful target in the
therapeutic intervention of human diseases involving ab-
normal apoptosis.
 
Materials and methods
 
Antibodies and other reagents
 
Rabbit antibodies against AKT, phospho-Akt(Ser473), phospho-
Akt(Thr308), PDK1, phosphor-PDK1(Ser241), p44/42 MAPK (Erk1/2), phos-
phor-p44/42 MAPK (Thr202/Tyr204), and phosphor-p38 MAPK (Thr180/
Tyr182) were from Cell Signaling Technology, Inc. Mouse antipaxillin
mAb (clone 349) was from BD Transduction Laboratories. IGF-1, FBS, and
cell culture media were from Invitrogen.
 
RNA interference
 
The sequences of CH-ILKBP siRNA were selected based on a method
described previously (Elbashir et al., 2002). The targeted sequence that ef-
fectively mediates the silencing of CH-ILKBP expression is 5
 
 
 
-AAUG-
AGGUGCGAACAAUGGUG-3
 
 
 
 (sense sequence). The 21-nucleotide syn-
thetic siRNA duplex was prepared by Dharmacon Research. HeLa cells
were transfected with the CH-ILKBP siRNA or a 21-nucleotide irrelevant
RNA duplex as a control using Oligofectamine (Invitrogen). Depletion of
CH-ILKBP was confirmed by Western blotting.
 
Immunofluorescent staining
 
Immunofluorescent staining was performed as described (Li et al., 1999;
Tu et al., 2001). Briefly, cells were plated on fibronectin-coated cover-
slips and cultured for 24 h. The cells were then fixed and stained with
anti–CH-ILKBP (Tu et al., 2001), anti-ILK (Li et al., 1999), and antipaxillin
mAbs. The mouse primary antibodies were detected with a Rhodamine
red
 
TM
 
–conjugated anti–mouse IgG antibody (Jackson ImmunoResearch
Laboratories).
 
DNA constructs and transfection
 
The DNA construct (pUSEamp(
 
 
 
)/myr-Akt1) encoding myristoylated Akt
was from Upstate Biotechnology. HeLa cells were transfected with pUSE-
amp(
 
 
 
)/myr-Akt1 or a pUSEamp(
 
 
 
) vector lacking Akt sequence as a
control using LipofectAmine PLUS (Invitrogen). To analyze subcellular
localization of ILK and PINCH-1, HeLa cells were transfected with
pEGFP-ILK and pEGFP–PINCH-1 expression vectors as described (Zhang
et al., 2002). 1 d after DNA transfection, the cells were transfected with
the CH-ILKBP siRNA or a 21-nucleotide irrelevant RNA duplex using
Oligofectamine (Invitrogen). The transfectants were plated on fibronec-
tin-coated 24 h after siRNA transfection and cultured for an additional 24 h.
The cells were fixed and analyzed by immunofluorescent staining as de-
scribed above.
 
Cell adhesion
 
Cells were starved in serum-free DME for 18–24 h and then harvested with
0.05% trypsin-EDTA. Cells were washed with serum-free DME containing
1% BSA, resuspended in the same medium, and kept in suspension for 2 h
at 37
 
 
 
C. The cells were either immediately collected and lysed with 1%
Triton X-100 in PBS containing protease inhibitors (lysis buffer) or allowed
to adhere on laminin-coated dishes for 30 min and then lazed. The cell ly-
sates were analyzed by Western blotting.
 
Serum and IGF-1 stimulation
 
Cells were starved in serum-free DME for 18–24 h and then stimulated
with DME containing FBS or IGF-1. At the end of stimulation, cells were
either immediately lysed with the lysis buffer and analyzed by Western
blotting or fractionated as described below.
 
Cell fractionation
 
Cytosol and membrane fractions were prepared as described (Scheid et al.,
2002). Briefly, cells were suspended in hypotonic lysis buffer (25 mM Tris,
pH 7.4, 5 mM EDTA, 1 mM dithiothreitol, 1 mM Na
 
3
 
VO
 
4
 
, 2.5 mM
Na
 
4
 
P
 
2
 
O
 
7
 
, and protease inhibitors) and disrupted by five passages through a
27-gauge needle. Large cell debris was pelleted by centrifugation at 2,000 
 
g
 
for 5 min at 4
 
 
 
C. The supernatants were centrifuged at 100,000 
 
g
 
 for 20 min
at 4
 
 
 
C. The resulting supernatant (cytosol) was collected, and the pellet
was resuspended in lysis buffer containing 1% Triton X-100. The lysate
was again centrifuged at 100,000 
 
g
 
 for 20 min at 4
 
 
 
C, and the supernatant
(membrane) was collected. The distributions of proteins in the cytosol and
membrane fractions were analyzed by Western blotting.
 
Apoptosis
 
Cells (as specified in each experiment) were cultured in DME supple-
mented with 10% FBS. Apoptosis was analyzed 48 h after RNA transfec-
tion using terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (TUNEL) and caspase-3 assays. The TUNEL assay was
performed using an In Situ Cell Death Detection kit (Roche). The cas-
pase-3 activities were measured using a colorimetric caspase-3 assay kit
from Calbiochem.
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